The U.S. Food and Drug Administration (FDA) has recently approved a groundbreaking eye drop named Vizz, featuring the active ingredient “ascledin,” specifically designed to treat age-related near vision loss, known as presbyopia.
Kabul 24: Presbyopia is a common condition that affects the eye’s ability to focus on close objects, typically impacting individuals over the age of 40.According to the manufacturer, a single application of Vizz can significantly enhance the depth of field and improve focus on near objects for up to 10 hours.
This innovative solution offers a non-invasive alternative to reading glasses or surgical procedures like LASIK or lens implants, which are commonly used to address presbyopia.
By providing a convenient and effective option, Vizz has the potential to transform the daily lives of millions, reducing dependency on corrective lenses and eliminating the need for costly and invasive surgeries.
The World Health Organization estimates that approximately 2.1 billion people worldwide suffer from varying degrees of near vision impairment, a number expected to rise as the global population ages.
Vizz’s ability to improve near vision with a single drop could enhance the quality of life for those affected, offering greater independence in tasks such as reading, using smartphones, or performing detailed work.
The manufacturer has announced that Vizz eye drops will be available on the market by the end of 2025, with expectations of widespread adoption due to its convenience and efficacy. This FDA approval marks a significant milestone in non-surgical presbyopia treatment, potentially setting a new standard in vision care.
As Vizz prepares to enter the market, it promises to redefine how age-related vision loss is managed, offering a practical and accessible solution for billions worldwide.
